Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of April 30, 2025 • 12:43 PM ET

Date/Time Source News Release
04/30/2025 08:11 AM EDT GlobeNewswire Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
04/28/2025 07:50 AM EDT GlobeNewswire Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug
03/26/2025 08:40 AM EDT GlobeNewswire Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
02/26/2025 01:30 PM EST GlobeNewswire Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
02/18/2025 08:50 AM EST GlobeNewswire Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
02/11/2025 07:45 AM EST GlobeNewswire Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
01/22/2025 08:29 AM EST GlobeNewswire Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment
01/08/2025 08:29 AM EST GlobeNewswire Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial
01/02/2025 08:45 AM EST GlobeNewswire Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain
12/18/2024 07:35 AM EST GlobeNewswire Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
Page

Additional News

As of April 30, 2025 • 12:43 PM ET

Date/Time Source News Release
04/30/2025 09:35 AM EDT InvestorBrandNetwork BioMedNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Preclinical Data for SP-26 Ketamine Implant 
04/28/2025 09:05 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application for Alzheimer's Drug SPC-14
04/25/2025 05:38 PM EDT SeekingAlpha Silo Pharma files to sell $4.72M shares of common stock, warrants
03/26/2025 09:30 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Begins Final Preclinical Study for PTSD Treatment SPC-15
03/24/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Monday, March 24th, 2025
03/24/2025 05:31 AM EDT US Earnings Reports Expected earnings - Silo Pharma Inc.
02/27/2025 09:31 AM EST InvestorBrandNetwork BioMedNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Secures USPTO Patent for PTSD Treatment SPC-15
02/18/2025 11:45 AM EST InvestorBrandNetwork InvestorNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Files Provisional Patent for SPC-15 Dual-Action Treatment
02/11/2025 08:30 AM EST InvestorBrandNetwork InvestorNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Early Data on SP-26 Ketamine Implant Study
01/22/2025 09:15 AM EST InvestorBrandNetwork InvestorNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Bolsters Intellectual Property with New Patent Filing for PTSD Treatment
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.